Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Halle CF Moore"'
Autor:
Ann H. Partridge, Samuel M. Niman, Monica Ruggeri, Fedro A. Peccatori, Hatem A. Azim, Jr., Marco Colleoni, Cristina Saura, Chikako Shimizu, Anna Barbro Sætersdal, Judith R. Kroep, Audrey Mailliez, Ellen Warner, Virginia F. Borges, Frédéric Amant, Andrea Gombos, Akemi Kataoka, Christine Rousset-Jablonski, Simona Borstnar, Junko Takei, Jeong Eon Lee, Janice M. Walshe, Manuel Ruíz Borrego, Halle CF. Moore, Christobel Saunders, Fatima Cardoso, Snezana Susnjar, Vesna Bjelic-Radisic, Karen L. Smith, Martine Piccart, Larissa A. Korde, Aron Goldhirsch, Richard D. Gelber, Olivia Pagani
Publikováno v:
Breast, Vol 59, Iss , Pp 327-338 (2021)
Background: Premenopausal women with early hormone-receptor positive (HR+) breast cancer receive 5–10 years of adjuvant endocrine therapy (ET) during which pregnancy is contraindicated and fertility may wane. The POSITIVE study investigates the imp
Externí odkaz:
https://doaj.org/article/e32b73f6538741fb915cc74aa4bb1fbe
Publikováno v:
Cancer Research. 82:P1-08
Background: Low muscle mass, known as sarcopenia, is associated with chemotherapy toxicity and reduced survival in women with breast cancer (BC). Sarcopenic obesity, a process in which patients lose muscle mass and increase body adipose mass, is asso
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7c881a494979cab543f2d272fa2c9b21
https://doi.org/10.1158/1538-7445.sabcs21-p1-08-04
https://doi.org/10.1158/1538-7445.sabcs21-p1-08-04
Publikováno v:
Cancer Research. 82:P5-14
Background: Delays in cancer care can have a detrimental impact on breast cancer outcomes. Despite advances in breast cancer treatment and improvements in survival, disparities between racial groups persist. At our own institution, we observed worse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::78aeee99996a7578ea6a77bccd9e9f7e
https://doi.org/10.1158/1538-7445.sabcs21-p5-14-13
https://doi.org/10.1158/1538-7445.sabcs21-p5-14-13
Publikováno v:
Pan African Medical Journal. 2016, Vol. 24, p1-6. 6p.
Autor:
Hatem A. Azim, Christobel Saunders, Anna Barbro Sætersdal, Ellen Warner, Marco Colleoni, Aron Goldhirsch, Andrea Gombos, Jeong Eon Lee, Janice M. Walshe, Fedro A. Peccatori, Martine Piccart, Christine Rousset-Jablonski, Simona Borštnar, Halle C. F. Moore, Manuel Ruiz Borrego, Karen L. Smith, Judith R. Kroep, Samuel M. Niman, Snezana Susnjar, Virginia F. Borges, Ann H. Partridge, Fatima Cardoso, Akemi Kataoka, Olivia Pagani, Cristina Saura, Chikako Shimizu, Hideko Yamauchi, Vesna Bjelic-Radisic, Richard D. Gelber, Monica Ruggeri, Larissa A. Korde
Publikováno v:
Cancer Research. 81:PS12-17
Background: Pregnancy is a major concern for young breast cancer (BC) survivors. Conception after BC in women with hormone receptor positive (HR+) disease is affected by the standard 5-10 years of adjuvant endocrine therapy (ET) during which pregnanc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f5022909e897244bc4e7d2fd5867b3ed
https://doi.org/10.1158/1538-7445.sabcs20-ps12-17
https://doi.org/10.1158/1538-7445.sabcs20-ps12-17
Autor:
Alberto J. Montero, Hanjie Mo, G. Thomas Budd, Jame Abraham, Halle C. F. Moore, Catherine E Renna, Susan B. LeGrand, Megan L. Kruse
Publikováno v:
Cancer Research. 81:PS12-18
Background: Everolimus in combination with exemestane (EVE+EXE) was initially FDA approved to treat metastatic hormone receptor-positive breast cancer (mHRBC) in patients previously treated with nonsteroidal aromatase inhibitors based on the BOLERO-2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::214f8e965fd5cafc6d9d0781bda6f245
https://doi.org/10.1158/1538-7445.sabcs20-ps12-18
https://doi.org/10.1158/1538-7445.sabcs20-ps12-18
Autor:
Hong Li, Halle C. F. Moore, G. Thomas Budd, Alberto J. Montero, Jame Abraham, Mathew Thomas, Megan L. Kruse
Publikováno v:
Cancer Research. 80:P2-14
Background: Invasive lobular breast cancer (ILC) is the second most common histological type of invasive breast cancer and accounts for 10-15% of all breast cancer cases. It is commonly strongly hormone receptor positive and, in general, is considere
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::82b55c35f02f3a6f8038310312e4bfcd
https://doi.org/10.1158/1538-7445.sabcs19-p2-14-13
https://doi.org/10.1158/1538-7445.sabcs19-p2-14-13